BioSig Technologies, Inc. (NASDAQ:BSGM), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, has announced that it will be presenting at the 26th Annual International Atrial Fibrillation Symposium, held virtually on January 29-31, 2021.
Clinical observations collected with BioSig’s PURE EP System will be presented by G. Joseph Gallinghouse, M.D., Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, during the 'Spotlight Session: Early Stage and Emerging New Technologies and Drugs in Cardiac EP' on January 29, 2021, from 2.40pm-3.40pm ET.
More than 470 patient cases have been conducted with the PURE EP System to date across seven clinical sites in the US. Dr Gallinghouse is one of the most experienced PURE EP physician users, having worked with the technology since 2019.
In a statement, Kenneth L. Londoner, chairman, and CEO of BioSig Technologies commented: “The annual AF Symposium is one of the industry's highlights, and we are particularly grateful to the organizers for opening up this outstanding event to the broader audience in 2021.
"All stakeholders, including patients and the financial community, are being presented with a unique opportunity to attend a highly educational industry event that would normally be reserved for peer-to-peer engagement. We look forward to contributing to the excellent scientific program and learning about the latest clinical advances from the faculty and our peers."
This year, the AF Symposium will be streamed live and can be attended free of charge. To register for the event, use the following link: https://events.r20.constantcontact.com/register/eventReg?oeidk=a07ehfsps50a7702ca6&oseq=&c=&ch=
Contact the author at email@example.com